These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 34614327)

  • 1. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
    Chemaitelly H; Tang P; Hasan MR; AlMukdad S; Yassine HM; Benslimane FM; Al Khatib HA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    N Engl J Med; 2021 Dec; 385(24):e83. PubMed ID: 34614327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Sukik L; Chemaitelly H; Ayoub HH; Coyle P; Tang P; Yassine HM; Al Thani AA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abdel-Rahman ME; Abu-Raddad LJ
    Vaccine; 2024 May; 42(14):3307-3320. PubMed ID: 38616439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
    Chemaitelly H; AlMukdad S; Ayoub HH; Altarawneh HN; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Al-Romaihi HE; Butt AA; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    N Engl J Med; 2022 Nov; 387(20):1865-1876. PubMed ID: 36322837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
    Altarawneh HN; Chemaitelly H; Ayoub HH; Tang P; Hasan MR; Yassine HM; Al-Khatib HA; Smatti MK; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    N Engl J Med; 2022 Jul; 387(1):21-34. PubMed ID: 35704396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D
    N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.
    Chemaitelly H; Ayoub HH; Coyle P; Tang P; Hasan MR; Yassine HM; Al Thani AA; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Influenza Other Respir Viruses; 2024 Oct; 18(10):e13357. PubMed ID: 39343986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning Immunity after the BNT162b2 Vaccine in Israel.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
    N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.
    Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Lancet Microbe; 2022 Dec; 3(12):e944-e955. PubMed ID: 36375482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Jiménez-Sepúlveda N; Gras-Valentí P; Chico-Sánchez P; Castro-García JM; Ronda-Pérez E; Vanaclocha H; Peiró S; Burgos JS; Ana Berenguer ; Navarro D; Sánchez-Payá J;
    Vaccine; 2024 Jul; 42(19):4011-4021. PubMed ID: 38760269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
    Hall V; Foulkes S; Insalata F; Kirwan P; Saei A; Atti A; Wellington E; Khawam J; Munro K; Cole M; Tranquillini C; Taylor-Kerr A; Hettiarachchi N; Calbraith D; Sajedi N; Milligan I; Themistocleous Y; Corrigan D; Cromey L; Price L; Stewart S; de Lacy E; Norman C; Linley E; Otter AD; Semper A; Hewson J; D'Arcangelo S; Chand M; Brown CS; Brooks T; Islam J; Charlett A; Hopkins S;
    N Engl J Med; 2022 Mar; 386(13):1207-1220. PubMed ID: 35172051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
    Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Nat Commun; 2022 Jun; 13(1):3082. PubMed ID: 35654888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.